Psychotic symptoms in tyrosine hydroxylase deficiency-associated dopa-responsive dystonia treated with antipsychotics and rTMS: a case report
- 1Department of Psychiatry, Huzhou Third Municipal Hospital
Abstract
Background: Tyrosine hydroxylase deficiency (THD) is a rare autosomal recessive disorder caused by mutations in the TH gene. THD encompasses a broad phenotypic spectrum that includes dopamine-responsive dystonia (DRD) as its milder presentation, alongside severe infantile parkinsonism and progressive infantile encephalopathy. Although non-motor manifestations—such as depression, anxiety, and sleep disturbances—have garnered increasing attention, psychotic symptoms including hallucinations and delusions remain rarely reported in THD.
Case summary: This report describes a genetically confirmed woman with THD who presented with infantile-onset dystonia. Auditory hallucinations and erotomanic delusions emerged approximately five years after levodopa initiation and persisted despite one-month levodopa withdrawal. Although levodopa markedly improved her dystonia, antipsychotic treatment posed a therapeutic dilemma: risperidone exacerbated motor symptoms, and aripiprazole was limited by poor adherence. A multimodal regimen comprising aripiprazole, quetiapine, and low-frequency repetitive transcranial magnetic stimulation (rTMS) targeting the left temporoparietal cortex was associated with progressive improvement of psychotic symptoms without clinically apparent worsening of dystonia. The independent contribution of rTMS could not be determined given the concurrent pharmacological titration.
Conclusion: Selecting appropriate antipsychotic medication in THD patients with prominent psychotic symptoms poses a considerable challenge. The combination of aripiprazole, quetiapine, and rTMS may represent a potential therapeutic option. To our knowledge, this is the first reported case of genetically confirmed DRD due to THD presenting with prominent psychotic symptoms, and among the few documenting rTMS use in this population. These observations are based on clinical assessment without standardized quantitative measures; the independent efficacy of rTMS cannot be established from this case.
Related
- Glucocorticoid replacement therapy and anthropometric features in patients with 21-hydroxylase deficiency in Japan: results from a nationwide epidemiological study
- Tyrosine Hydroxylase Deficiency: From Clinical and Therapeutic Features to Pathogenetic Considerations
- Ultra-rare coding variants in schizophrenia risk genes are associated with longitudinal phenotypic differences across psychotic disorders
- Case Report: Hyperactive delirium with psychotic symptoms associated with severe hypothyroidism during pembrolizumab therapy. Complete remission after levothyroxine and no recurrence after pembrolizumab rechallenge
- Alternative Splicing of Homologous Recombination Genes Is Associated with Homologous Recombination Deficiency and Immunoregulatory Phenotypes in Breast Cancer
BibTeX
@article{shen2026psychotic,
title = {{Psychotic symptoms in tyrosine hydroxylase deficiency-associated dopa-responsive dystonia treated with antipsychotics and rTMS: a case report}},
author = {Yue Shen and Hai-Zhi Chen and Liang Lv and Lan-lan Fang},
journal = {Frontiers in Psychiatry},
year = {2026},
month = oct,
doi = {10.3389/fpsyt.2026.1920048},
url = {https://www.frontiersin.org/articles/10.3389/fpsyt.2026.1920048/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Psychotic symptoms in tyrosine hydroxylase deficiency-associated dopa-responsive dystonia treated with antipsychotics and rTMS: a case report
AU - Yue Shen
AU - Hai-Zhi Chen
AU - Liang Lv
AU - Lan-lan Fang
PY - 2026
DA - 2026/10/08
JO - Frontiers in Psychiatry
DO - 10.3389/fpsyt.2026.1920048
UR - https://www.frontiersin.org/articles/10.3389/fpsyt.2026.1920048/full
AB - Background: Tyrosine hydroxylase deficiency (THD) is a rare autosomal recessive disorder caused by mutations in the TH gene. THD encompasses a broad phenotypic spectrum that includes dopamine-responsive dystonia (DRD) as its milder presentation, alongside severe infantile parkinsonism and progressive infantile encephalopathy. Although non-motor manifestations—such as depression, anxiety, and sleep disturbances—have garnered increasing attention, psychotic symptoms including hallucinations and delusions remain rarely reported in THD. Case summary: This report describes a genetically confirmed woman with THD who presented with infantile-onset dystonia. Auditory hallucinations and erotomanic delusions emerged approximately five years after levodopa initiation and persisted despite one-month levodopa withdrawal. Although levodopa markedly improved her dystonia, antipsychotic treatment posed a therapeutic dilemma: risperidone exacerbated motor symptoms, and aripiprazole was limited by poor adherence. A multimodal regimen comprising aripiprazole, quetiapine, and low-frequency repetitive transcranial magnetic stimulation (rTMS) targeting the left temporoparietal cortex was associated with progressive improvement of psychotic symptoms without clinically apparent worsening of dystonia. The independent contribution of rTMS could not be determined given the concurrent pharmacological titration. Conclusion: Selecting appropriate antipsychotic medication in THD patients with prominent psychotic symptoms poses a considerable challenge. The combination of aripiprazole, quetiapine, and rTMS may represent a potential therapeutic option. To our knowledge, this is the first reported case of genetically confirmed DRD due to THD presenting with prominent psychotic symptoms, and among the few documenting rTMS use in this population. These observations are based on clinical assessment without standardized quantitative measures; the independent efficacy of rTMS cannot be established from this case.
SN - 1664-0640
ER -